NRG-GI012

Open to Accrual

Return to Protocol Table

Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT)

Principal Investigator

Jennifer Wo, MD,

Status

Open to Accrual

Date Opened To Accrual

October 07 2025

Disease Site

Gastrointestinal [GI]

Liver

Phase

III

Developmental Therapeutics

Primary Objective

To determine if liver SBRT in combination with IO-based systemic therapy improves survival compared to IO-based systemic therapy alone, in patients with hepatocellular cancer with macrovascular invasion.

Patient Population

Diagnosis of hepatocellular cancer (HCC). HCCmacrovascular invasion, defined as enhancing vascular thrombosis demonstratingarterial enhancement and venous or delayed venous washout on multiphasic MRIand/or CT.

Target Accrual

226

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.